For clients declining CHOP, the three evidence-supported alternatives are single-agent doxorubicin (DOX) plus prednisone, single-agent rabacfosadine (RAB), and alternating RAB/DOX — each offering a meaningful step up from prednisone alone while requiring substantially fewer visits than CHOP.
Prednisone alone is the floor, not a treatment. Median survival time (MST) with prednisone alone is 1–2 months, compared to approximately 1 year with CHOP. AAHA Clinical G… It is appropriate only when all chemotherapy is declined.
Single-agent DOX plus prednisone is the most practical step-down from CHOP for B-cell lymphoma. DOX is administered once every 3 weeks for 5–6 treatments — 5 to 6 visits total versus 12–17 for CHOP. BMC Veterinary… Overall response rates are 74–88%, with remission durations of 4–6 months and survival times of 5–9 months. BMC Veterinary… Critically, these outcomes are drawn from mixed immunophenotype populations; dogs with B-cell lymphoma specifically show a 100% response rate to a single DOX dose, compared to 50% for T-cell lymphoma, so this protocol is best reserved for confirmed B-cell disease. BMC Veterinary… The AAHA guidelines list single-agent chemotherapy as an accepted option with MST under 1 year. AAHA Clinical G…
Rabacfosadine (RAB, Tanovea-CA1) at 1.0 mg/kg IV every 21 days for up to 5 treatments is FDA-conditionally approved for canine lymphoma and is an established single-agent alternative. Journal of Vete…+1 As a single agent, RAB achieves response rates of 74–100% across naïve and relapsed disease. Journal of Vete… In a placebo-controlled trial, RAB produced a median progression-free survival (PFS) of 82 days overall versus 21 days for placebo; in treatment-naïve dogs specifically, median PFS was 143 days versus 19 days for placebo. Journal of Vete… The overall best objective response rate was 73.2% for RAB versus 5.6% for placebo. Journal of Vete… The AAHA guidelines report an MST of approximately 6 months with RAB. AAHA Clinical G… Response rates and durations are better in B-cell than T-cell lymphoma, and in dogs with fewer prior treatment lines. Journal of Vete…
Alternating RAB/DOX is the highest-efficacy reduced-visit alternative, with PFS comparable to CHOP at only 6 total treatments. The protocol alternates RAB 1.0 mg/kg IV with DOX 30 mg/m² IV every 21 days. Veterinary and… The original evaluation reported an overall response rate (ORR) of 84% (68% complete response) and a median PFS of 194 days. Journal of Vete… A subsequent prospective trial in 59 treatment-naïve dogs confirmed the protocol. Veterinary and… The 194-day median PFS is comparable to PFIs reported after CHOP-based treatment (140–219 days) and superior to single-agent DOX (median response durations 80.5–169 days). Journal of Vete… This protocol requires only 6 visits versus 12–16 for CHOP. Journal of Vete…
| Protocol | Dose / Schedule | ORR | Median PFS / Survival | Key Caveat |
|---|---|---|---|---|
| Prednisone alone | Standard anti-inflammatory dosing | Not reported | MST 1–2 months AAHA Clinical G… | Not a chemotherapy option; floor only |
| DOX + prednisone | DOX q21d × 5–6 treatments BMC Veterinary… | 74–88% BMC Veterinary… | Remission 4–6 mo; MST 5–9 mo BMC Veterinary… | Best for confirmed B-cell; inferior to CHOP BMC Veterinary… |
| RAB single agent | 1.0 mg/kg IV q21d × up to 5 treatments Journal of Vete…+1 | 73.2% Journal of Vete… | PFS 82 days (naïve: 143 days) Journal of Vete…; MST ~6 mo AAHA Clinical G… | Better in B-cell and naïve disease Journal of Vete… |
| Alternating RAB/DOX | RAB 1.0 mg/kg IV alternating with DOX 30 mg/m² IV q21d × 6 total Veterinary and… | 84% (68% CR) Journal of Vete… | PFS 194 days Journal of Vete… | PFS comparable to CHOP at 6 visits vs 12–16 Journal of Vete… |
Would you like to discuss the adverse event profiles and monitoring requirements for rabacfosadine versus doxorubicin in these reduced-visit protocols?